Methods of treating cancer

A cancer and cancer cell technology, applied in biochemical equipment and methods, pharmaceutical formulations, microbial measurement/inspection, etc., can solve the problem of reducing the proliferation ability of cancer cells

Pending Publication Date: 2019-09-10
GLAXOSMITHKLINE INTPROP DEV LTD
View PDF22 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In many of these experimental systems, disruption of PRMT1-dependent ADMA modification of its substrates reduced the proliferative capacity of cancer cells (Yang, Y. & Bedford, M.T. Protein arginine methyltransferases and cancer. Nat Rev Cancer 13, 37-50, doi: 10.1038 / nrc3409(2013))

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods of treating cancer
  • Methods of treating cancer
  • Methods of treating cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0283] Arginine methylation and PRMT

[0284] Arginine methylation is an important post-translational modification of proteins involved in various cellular processes, such as gene regulation, RNA processing, DNA damage response, and signal transduction. Proteins containing methylated arginine are present in the nucleus and cytoplasmic components, indicating that enzymes that catalyze the transfer of methyl groups to arginine are also present in these subcellular compartments (reviewed in Yang, Y. & Bedford, MTProtein arginine methyltransferases and cancer.Nat Rev Cancer13,37-50,doi:10.1038 / nrc3409(2013); Lee,YH&Stallcup,MRMinireview:proteinarginine methylation of nonhistone proteins in transcriptional regulation.MolEndocrinol23,425-433,doi:10.1210 / me.2008-0380(2009)). In mammalian cells, methylated arginine exists in three main forms: ω-N G -Monomethyl-arginine (MMA), ω-N G ,N G -Asymmetric dimethylarginine (ADMA) or ω-N G ,N’ G -Symmetric dimethylarginine (SDMA). Each methyla...

Embodiment 2

[0368] Predictive biomarkers

[0369] The sensitivity ranking of the cell line to compound A (by gIC50) and the relationship with somatic changes or gene expression were examined using genomic data obtained through Cancer Cell Line Encylopedia (CCLE). In addition, lymphoma cell lines are graded by their ability to subject Compound A to a cytotoxic response. Using this method, it can be determined that there is no obvious correlation with any cancer-related changes, which may be due to the extensive activity of compound A in cell culture. Therefore, a reasonable approach was investigated based on the combined activity observed with PRMT5 inhibition.

[0370] Recent studies describe the mechanism by which the loss of 5-methylthioadenosine phosphorylase (MTAP) gene may inhibit endogenous PRMT5 in tumor cells. The MTAP gene is frequently deleted in cancers, including 40% of glioblastoma, 25% of melanoma and pancreatic cancer, and 15% of non-small cell lung cancer. (Mavrakis, KJ et a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to methods of treating cancer in a subject in need thereof, e.g., in a human in need thereof, comprising determining determining the level of 5- Methylthioadenosine phosphorylase(MTAP) polynucleotide or polypeptide or the presence or absence of a mutation in MTAP in a sample from the human, and administering to the human an effective amount of a Type I protein arginine methyltransferase (Type I PRMT) inhibitor if the level of the MTAP polynucleotide or polypeptide is decreased relative to a reference or if a mutation in MTAP polynucleotide or polypeptide is present, thereby treating the cancer in the human.

Description

Technical field [0001] The present invention relates to methods of treating cancer in a subject in need. Background technique [0002] Effective treatment of hyperproliferative diseases, including cancer, is an ongoing goal in the field of oncology. Generally, cancer is caused by a disorder of the normal processes that control cell division, differentiation, and apoptotic cell death, and is characterized by the proliferation of malignant cells, which have the potential for unlimited growth, local expansion, and systemic metastasis. Disorders of normal processes include abnormalities in signal transduction pathways and responses to factors different from those found in normal cells. [0003] The expanded development and use of targeted therapies for cancer treatment reflects the growing understanding of key carcinogenic pathways and how targeted perturbations of these pathways correspond to clinical responses. The difficulty in predicting the efficacy of targeted therapies may be ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/6886A61K31/415A61K31/4155
CPCA61K31/415A61K31/4155C12Q1/6886C12Q2600/106C12Q2600/158G01N2800/52A61P35/00A61K45/06G01N33/6893
Inventor A.费多里夫S.格哈特R.G.克鲁格J.拉莱奥H.穆罕默德S.奥布赖恩J.鲁宾
Owner GLAXOSMITHKLINE INTPROP DEV LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products